Emcure Pharmaceuticals Limited (EMCURE)
Unaudited Financial Results (Standalone and consolidated) for the quarter ended June 30, 2026
Q1FY27 results (unaudited):
Standalone:
Revenue 14.5bn +32% y-y (10.97bn)
PAT 2.0bn +63% y-y (1.23bn)
Consolidated:
Revenue 25.8bn +23% y-y (21.0bn)
EBITDA 5.1bn +26% y-y (4.0bn)
EBITDA margin 19.7% (19.2%) +50 bps y-y
PAT 2.9bn +36% y-y (2.1bn)
Dividend: Not stated
Commentary: Emcure starts FY27 on a strong note; Q1 revenue grows 23% and PAT rises 36%. Domestic business grew 10.2%, international business grew 34.2%. EBITDA margin improved by ~50 bps reflecting productivity gains and operating leverage.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 EMCURE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add EMCURE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Emcure Pharmaceuticals Limited
Important.
The summary above is generated automatically from Emcure Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.